Guideline Video

Guideline Resources

  • Management of Relapsed/Refractory Disease in Adolescents and Young Adults with Acute Lymphoblastic Leukemia
  • American Society of Hematology
  • February 11th, 2026
  • Overview
  • Full-text

Video Transcription

Just published February 11th, 2026, The American Society of Hematology’s newest guideline on Management of Relapsed/Refractory Disease in Adolescents and Young Adults with Acute Lymphoblastic Leukemia.

The purpose of this guideline is to aid clinicians in the management of adolescents and young adults, or AYAs, with relapsed/refractory acute lymphoblastic leukemia, or ALL. We’ll just be going over a summary of these 8 recommendations. Let’s get started. 

  • Blinatumomab is recommended over chemotherapy for AYAs with relapsed/refractory B- cell ALL.  
  • Inotuzumab is recommended over chemotherapy for AYAs with relapsed/refractory B- cell ALL. 
  • The guideline suggests further consolidation with allogeneic hematopoietic stem cell transplantation for HSCT-naïve AYAs with relapsed B-cell ALL who achieve a second remission using autologous CD19 CAR-T products. 
  • The guideline suggests allogeneic hematopoietic stem cell transplantation for AYAs with relapsed B-cell ALL over chemotherapy alone.  
  • The guideline suggests myeloblative conditioning over chemotherapy alone for AYAs who have relapsed/refractory ALL with allogeneic hematopoietic stem cell transplantation. 
  • The guideline recommends that AYAs with isolated CNS relapse of ALL receive CNS-directed therapy .
  • The guideline recommends against AYAs with isolated CNS relapse of ALL receiving CNS radiation as sole management. 
  • The guideline suggests a nelarabine-containing regimen for AYAs with relapsed/refractory T-cell ALL.

And there you have it. Make sure to check out the full guideline from the The American Society of Hematology and other related clinical decision support tools at guidelinecentral.com.

Sign up for alerts and stay informed on the latest published articles and guidelines.

Copyright © 2026 Guideline Central, all rights reserved.